Publication: Antimicrobial Agents and Chemotherapy
Abstract
Diethylcarbamazine (DEC) is a key drug for treating and preventing lymphatic filariasis through mass drug administration, but its population pharmacokinetics in infected versus healthy individuals had not been directly compared. This study in 56 adults (32 infected, 24 uninfected) in Côte d'Ivoire built a population pharmacokinetic model using Phoenix NLME, examining covariates including infection status, body weight, sex, and renal and liver function. Body weight and gender were identified as significant covariates for DEC's volume of distribution, with simulations showing body weight meaningfully affects drug exposure in both sexes. This population pharmacokinetic model supports future research into DEC drug-drug interactions within combination mass drug administration regimens for lymphatic filariasis.
Author(s): Bala V, Chhonker YS, Alshehri A, Edi C, Bjerum CM, Koudou BG, King CL, Murry DJ
Published: 2021 年 7 月 26 日
Phoenix NLME：Comparing Infected and Healthy Patients
Phoenix NLME's population model identified body weight and gender as key drivers of drug exposure in this lymphatic filariasis study. Phoenix NLME is also available through RsNLME, bringing population PK/PD modeling into R for teams who prefer that environment, within a Phoenix platform accessible from any browser, on any device.
